SBIR/STTR Reauthorized Through 2031: What S. 3971 Changes for Applicants, Commercialization, and University IP Strategy
On April 13, 2026, the White House announced that S. 3971, the Small Business Innovation and Economic Security Act, had been signed into law. The measure reauthorizes and amends the SBIR and STTR programs through September 30, 2031. That timing matters: the prior authorization expired on September 30, 2025, so this law closes a 195-day lapse in formal authorization—just over six months of uncertainty for founders, small R&D companies, university spinouts, and grant teams planning around SBIR/STTR.
The headline is not simply that SBIR/STTR is back. Congress used this reauthorization to tighten research security, add a new scale-up path for later-stage technologies, improve Phase III transition, impose proposal-volume controls, expand commercialization support, and extend a wide range of program tools and pilots that matter in practice for applicants and agencies alike.
The biggest changes include:
- Stronger foreign-risk and research-security screening. Agencies must now evaluate whether an applicant presents a security risk using due diligence, disclosures, and coordination with intelligence, law-enforcement, and counterintelligence resources. The law also broadens due diligence to cover cybersecurity practices, foreign ownership and financial obligations, foreign affiliations, investment relationships, licensing agreements or joint ventures, and business relationships tied to foreign countries of concern or entities on specified federal lists. Where appropriate, applicants denied on security grounds are to receive notice, and the law clarifies that a denial in one cycle does not automatically bar a later application. It also extends a GAO study of security risks from three years to eight years.
- A new Phase II “strategic breakthrough” funding lane. Agencies whose required SBIR expenditure exceeds $100 million can establish a “strategic breakthrough allocation” of up to 0.50% of their extramural R&D budget from within SBIR. Under that authority, agencies can make Phase II awards of up to $30 million over as long as 48 months. To qualify, a company must already have at least one prior Phase II award, demonstrate 100% matching funds from new private capital and/or non-SBIR government funding, and show that the technology is an effective solution based on market research. For DoD, extra transition and acquisition-commitment requirements apply, and agencies are directed to use streamlined contracting mechanisms. Congress also required agencies to brief lawmakers on whether they plan to use this authority, so founders should view it as a powerful new option—not an automatic new pot of money.
- Proposal-volume controls beginning in FY2027. Each agency’s SBIR/STTR office must set a limit on how many Phase I and Phase II proposals a single company may submit, using a fiscal-year, solicitation-based, or topic-based method. Waivers are allowed only for time-sensitive, mission-urgent topics, require written justification plus approval within 15 days, and cannot cover more than 5% of an agency’s topics in a fiscal year. In practice, this is likely to reward more selective, better-positioned submissions over high-volume filing strategies.
- A bigger push on Phase III transition. The law requires training for contracting officers and the acquisition workforce on Phase III authorities, data rights, and sole-source award execution. It also directs procurement center representatives to advocate for the maximum practicable use of SBIR/STTR-developed technologies in Phase III, while telling agencies to develop simplified procedures, model contracts, and clearer solicitation language around Phase III eligibility and follow-on contracting.
- More flexible technical and business assistance (TABA). Awardees will have more control over how they use commercialization support funds. Agencies must authorize recipients to select technical and business assistance if desired, and the law adds cybersecurity assistance and foreign-involvement screening to the eligible support mix. It also allows those funds to be used to hire or augment staff for these activities. The statute sets assistance levels of up to $6,500 for Phase I and $50,000 for Phase II, and agencies with I-Corps programs must offer SBIR/STTR recipients a path to request participation in I-Corps or an equivalent training program.
- Better tracking of outcomes and follow-on use. The SBIR database and the Federal Procurement Data System must now track whether awards are direct-to-Phase II, subsequent Phase II, strategic breakthrough awards, Phase III prime contracts, or Phase III subcontracts. Federal systems must also identify when non-SBIR contracts are using SBIR/STTR-funded technology and connect Phase II and Phase III awards back to the relevant earlier SBIR/STTR work. That should make commercialization and transition performance more visible over time.
- Pilot authorities and flexibilities extended through 2031. Beyond the core reauthorization, the act extends a long list of operating authorities through September 30, 2031, including phase flexibility, the Commercialization Readiness Program for civilian agencies, accelerated awards, the Phase 0 pilot, administrative assistance, increased minimum performance standards, commercialization assistance pilots, the due diligence program, the STTR military research institution pilot, the budget calculation pilot, and the SOCOM pilot. It also allows agencies to carry over remaining FY2026 SBIR/STTR funds into FY2027. Phase flexibility was also updated to explicitly include the Department of Energy, NASA, and STTR.
For grant writers and applicants, this means the competitive bar is shifting. A winning submission now needs to be more than scientifically strong. Teams should be ready with tighter ownership and foreign-ties documentation, clearer commercialization evidence, stronger transition logic, and a more realistic account of how an agency will buy, test, deploy, or integrate the technology after Phase II. For some applicants—especially in defense, dual-use, and platform technologies—the new law makes matching capital, milestone-based development planning, and customer pull even more important.
That is exactly where strong proposal development matters. At ScienceDocs, we have supported SBIR/STTR applicants since 2004 and helped clients secure more than $1 billion in competitive research funding across NIH, NSF, DoD, DOE, and other SBIR/STTR agencies. Our expert SBIR/STTR grant writer and Commercialization support teams work at the co-PI level, supporting founders and innovators across Phase I, Phase II, Fast-Track, and resubmissions with proposal strategy, technical development, commercialization positioning, and compliance support.
And for startups looking to build around licensable university technology, our IP-LINK platform is especially relevant right now. IP-LINK is a global, funding-aware university IP discovery platform that connects licensable university technologies with active grant opportunities and commercialization strategy, helping startups, investors, researchers, and tech-transfer teams evaluate IP and funding pathways in one place. For teams pursuing spinout or license-first SBIR strategies, that combination can be a major advantage.
After a 195-day lapse in formal authorization, SBIR/STTR is not just back—it is back with sharper security rules, stronger commercialization expectations, better Phase III infrastructure, and a new strategic funding path for technologies that can credibly move toward deployment. The teams that move early, and move with disciplined proposal strategy, will be best positioned to capitalize!
Contact us for help with your SBIR grant, commercialization or TABA support.